2026 Q2 -tulosraportti
Vain PDF
13 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 000 | NRD | AVA | ||
| 2 700 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8.7.Very successful capital raising where surely a couple of new investors took the profit from approx. 36 down to approx. 16 vs. the discount they received. Easy small gains. The big gain lies with MDR approval and Draeger sales potentially already in q3./sales q4. That premise contains a small risk in my world, so one can see the current price of approx. 16 as a significant discount. Just MDR approval is in my calculation min. approx. 3x of today's price. We are talking about a stock of products with a large margin ready to roll out and a monopoly in a market that is not sensitive to economic cycles. It is my personal holding that precisely when we in the coming years will see a lot of volatility and AI hype disappoint, then this type of medicare/healtcare investments will stand very strong. We are so close now.- ·29.1.So there is good news which I interpret as progress and very positive. https://www.linkedin.com/posts/monivent_monivent-neonatology-activity-7422640814150815746-c-5m?utm_source=share&utm_medium=member_ios&rcm=ACoAAEcs4eMBJoVUYazg2avgusLt-Hqu6EkvxFw
- ·23.1.Really great work by the management and the team on the way to launch. The products are there now, a bit more liquidity needs to be found to execute for the rest of 2026. Just look at all the long-term owners, they are holding on and know that Monivent are the ONLY ones currently to take the market in EU and USA. One must remember it is a market of several Billion SEK to save the small lives. A bit more capital is needed, so some get cold feet and sell out, but here is an exciting case. I see a good acquisition opportunity and am not nervous about an increase in share capital or new investors at this level, I believe in huge upside market potential considering.
·22.12.2025This is a fantastic product that could be as groundbreaking as when the Anne doll and the standard pocket mask came out. It is extremely difficult to ventilate premature infants and newborns correctly. With such monitoring and feedback as this product provides, there are great opportunities to save lives and simplify correct ventilation. Dräger is big in blood gas within healthcare enterprises. So, a collaboration with them would carry significant weight. But then the question is whether they will invest together or if they will aim to acquire a potential bankruptcy estate and the patent. FDA approval is very critical for selling in the USA, where much revolves around documentation. I hope news comes soon that can point towards FDA approval, and then Dräger will be able to roll out this fantastic product at a high pace. Should also look at a similar solution for adults, as ventilation is difficult to perform correctly. Should be part of somewhat advanced first aid to achieve correct ventilation. (Breaths)!It is a fantastic product with a greater purpose. We are close, and my guess is that the FDA has the case. This follows what appears to be a really good preliminary study. (I just found this online after intense searching) https://www.sciencedirect.com/science/article/pii/S2666520425002693?via%3Dihub I don't know if you are new to this stock, but I don't think we have a bankruptcy here. We have 2 crucial patents and a super super super product that, precisely because of patents, could potentially achieve a unique and dominant position. We also have a super skilled, passionate CEO here, a strong team, a truly skilled and competent chairman of the board, and regarding your mention of bankruptcy - the largest shareholder with just under 20% who knows what he's doing. And who has shown great commitment with a loan here at the finish line. Likewise, other leading figures backed it up. So again, no bankruptcy here in my clear conviction. Yes, we are hopefully right at the finish line after several capital increases. Drraeger is a super partner, and if they are not a partner in distribution and sales, they will buy the whole shop, but why sell if you are ready to operate.. That is my analysis. Good luck.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 30 000 | 0 | 30 000 | 0 |
| Nordnet Bank AB | 2 700 | 0 | 2 700 | 0 |
| Avanza Bank AB | 0 | 32 700 | −32 700 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 0 | 32 700 | −32 700 | 0 |
| Nordnet Bank AB | 2 700 | 0 | 2 700 | 0 |
| Nordea Bank Abp | 30 000 | 0 | 30 000 | 0 |
2026 Q2 -tulosraportti
Vain PDF
13 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8.7.Very successful capital raising where surely a couple of new investors took the profit from approx. 36 down to approx. 16 vs. the discount they received. Easy small gains. The big gain lies with MDR approval and Draeger sales potentially already in q3./sales q4. That premise contains a small risk in my world, so one can see the current price of approx. 16 as a significant discount. Just MDR approval is in my calculation min. approx. 3x of today's price. We are talking about a stock of products with a large margin ready to roll out and a monopoly in a market that is not sensitive to economic cycles. It is my personal holding that precisely when we in the coming years will see a lot of volatility and AI hype disappoint, then this type of medicare/healtcare investments will stand very strong. We are so close now.
- ·29.1.So there is good news which I interpret as progress and very positive. https://www.linkedin.com/posts/monivent_monivent-neonatology-activity-7422640814150815746-c-5m?utm_source=share&utm_medium=member_ios&rcm=ACoAAEcs4eMBJoVUYazg2avgusLt-Hqu6EkvxFw
- ·23.1.Really great work by the management and the team on the way to launch. The products are there now, a bit more liquidity needs to be found to execute for the rest of 2026. Just look at all the long-term owners, they are holding on and know that Monivent are the ONLY ones currently to take the market in EU and USA. One must remember it is a market of several Billion SEK to save the small lives. A bit more capital is needed, so some get cold feet and sell out, but here is an exciting case. I see a good acquisition opportunity and am not nervous about an increase in share capital or new investors at this level, I believe in huge upside market potential considering.
- ·22.12.2025This is a fantastic product that could be as groundbreaking as when the Anne doll and the standard pocket mask came out. It is extremely difficult to ventilate premature infants and newborns correctly. With such monitoring and feedback as this product provides, there are great opportunities to save lives and simplify correct ventilation. Dräger is big in blood gas within healthcare enterprises. So, a collaboration with them would carry significant weight. But then the question is whether they will invest together or if they will aim to acquire a potential bankruptcy estate and the patent. FDA approval is very critical for selling in the USA, where much revolves around documentation. I hope news comes soon that can point towards FDA approval, and then Dräger will be able to roll out this fantastic product at a high pace. Should also look at a similar solution for adults, as ventilation is difficult to perform correctly. Should be part of somewhat advanced first aid to achieve correct ventilation. (Breaths)!It is a fantastic product with a greater purpose. We are close, and my guess is that the FDA has the case. This follows what appears to be a really good preliminary study. (I just found this online after intense searching) https://www.sciencedirect.com/science/article/pii/S2666520425002693?via%3Dihub I don't know if you are new to this stock, but I don't think we have a bankruptcy here. We have 2 crucial patents and a super super super product that, precisely because of patents, could potentially achieve a unique and dominant position. We also have a super skilled, passionate CEO here, a strong team, a truly skilled and competent chairman of the board, and regarding your mention of bankruptcy - the largest shareholder with just under 20% who knows what he's doing. And who has shown great commitment with a loan here at the finish line. Likewise, other leading figures backed it up. So again, no bankruptcy here in my clear conviction. Yes, we are hopefully right at the finish line after several capital increases. Drraeger is a super partner, and if they are not a partner in distribution and sales, they will buy the whole shop, but why sell if you are ready to operate.. That is my analysis. Good luck.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 000 | NRD | AVA | ||
| 2 700 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 30 000 | 0 | 30 000 | 0 |
| Nordnet Bank AB | 2 700 | 0 | 2 700 | 0 |
| Avanza Bank AB | 0 | 32 700 | −32 700 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 0 | 32 700 | −32 700 | 0 |
| Nordnet Bank AB | 2 700 | 0 | 2 700 | 0 |
| Nordea Bank Abp | 30 000 | 0 | 30 000 | 0 |
2026 Q2 -tulosraportti
Vain PDF
13 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8.7.Very successful capital raising where surely a couple of new investors took the profit from approx. 36 down to approx. 16 vs. the discount they received. Easy small gains. The big gain lies with MDR approval and Draeger sales potentially already in q3./sales q4. That premise contains a small risk in my world, so one can see the current price of approx. 16 as a significant discount. Just MDR approval is in my calculation min. approx. 3x of today's price. We are talking about a stock of products with a large margin ready to roll out and a monopoly in a market that is not sensitive to economic cycles. It is my personal holding that precisely when we in the coming years will see a lot of volatility and AI hype disappoint, then this type of medicare/healtcare investments will stand very strong. We are so close now.
- ·29.1.So there is good news which I interpret as progress and very positive. https://www.linkedin.com/posts/monivent_monivent-neonatology-activity-7422640814150815746-c-5m?utm_source=share&utm_medium=member_ios&rcm=ACoAAEcs4eMBJoVUYazg2avgusLt-Hqu6EkvxFw
- ·23.1.Really great work by the management and the team on the way to launch. The products are there now, a bit more liquidity needs to be found to execute for the rest of 2026. Just look at all the long-term owners, they are holding on and know that Monivent are the ONLY ones currently to take the market in EU and USA. One must remember it is a market of several Billion SEK to save the small lives. A bit more capital is needed, so some get cold feet and sell out, but here is an exciting case. I see a good acquisition opportunity and am not nervous about an increase in share capital or new investors at this level, I believe in huge upside market potential considering.
- ·22.12.2025This is a fantastic product that could be as groundbreaking as when the Anne doll and the standard pocket mask came out. It is extremely difficult to ventilate premature infants and newborns correctly. With such monitoring and feedback as this product provides, there are great opportunities to save lives and simplify correct ventilation. Dräger is big in blood gas within healthcare enterprises. So, a collaboration with them would carry significant weight. But then the question is whether they will invest together or if they will aim to acquire a potential bankruptcy estate and the patent. FDA approval is very critical for selling in the USA, where much revolves around documentation. I hope news comes soon that can point towards FDA approval, and then Dräger will be able to roll out this fantastic product at a high pace. Should also look at a similar solution for adults, as ventilation is difficult to perform correctly. Should be part of somewhat advanced first aid to achieve correct ventilation. (Breaths)!It is a fantastic product with a greater purpose. We are close, and my guess is that the FDA has the case. This follows what appears to be a really good preliminary study. (I just found this online after intense searching) https://www.sciencedirect.com/science/article/pii/S2666520425002693?via%3Dihub I don't know if you are new to this stock, but I don't think we have a bankruptcy here. We have 2 crucial patents and a super super super product that, precisely because of patents, could potentially achieve a unique and dominant position. We also have a super skilled, passionate CEO here, a strong team, a truly skilled and competent chairman of the board, and regarding your mention of bankruptcy - the largest shareholder with just under 20% who knows what he's doing. And who has shown great commitment with a loan here at the finish line. Likewise, other leading figures backed it up. So again, no bankruptcy here in my clear conviction. Yes, we are hopefully right at the finish line after several capital increases. Drraeger is a super partner, and if they are not a partner in distribution and sales, they will buy the whole shop, but why sell if you are ready to operate.. That is my analysis. Good luck.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 000 | NRD | AVA | ||
| 2 700 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 30 000 | 0 | 30 000 | 0 |
| Nordnet Bank AB | 2 700 | 0 | 2 700 | 0 |
| Avanza Bank AB | 0 | 32 700 | −32 700 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 0 | 32 700 | −32 700 | 0 |
| Nordnet Bank AB | 2 700 | 0 | 2 700 | 0 |
| Nordea Bank Abp | 30 000 | 0 | 30 000 | 0 |